Breast cancer
Specific antibodies:
The drug scaituzumab govitecan
Scaituzumab govitecan is a conjugated antibody medication that destroys cancer cells via the TROP-2 pathway and is most effective for patients with triple-negative breast cancer (TNBC).
The drug Pertuzumab
Pertuzumab is a monoclonal antibody that destroys HER2 pathway cancer cells and is most effective for HER-2 positive breast cancer patients.
Trastuzumab is an anticancer drug
Trastuzumab is a monoclonal antibody medication conjugate that destroys cancer cells on the HER2 pathway and provides cancer cells with toxic drugs. Patients with metastatic HER2 breast cancer benefit the most.
Emtansine trastuzumab
Trastuzumab emtansine is an antibody-drug conjugate that works on the HER2 pathway to destroy cancer cells. It is the optimal therapy option for patients with HER-2-positive breast cancer.
Trastuzumab derived from deruxtecan
Trastuzumab deruxtecan is a conjugate of an antibody and a cytotoxic drug that kills cancer cells on the HER2 pathway and supplies tumor cells with toxic drugs so they can burst readily. It is most effective for patients with metastatic HER2+ breast cancer.
